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Perineural invasionNerve ﬁbers accompany blood and lymphatic vessels all over the body. An extensive amount of knowledge
has been obtained with regard to tumor angiogenesis and tumor lymphangiogenesis, yet little is known about
the potential biological effects of “neoneurogenesis”. Cancer cells can exploit the advantage of the factors
released by the nerve ﬁbers to generate a positive microenvironment for cell survival and proliferation. At the
same time, they can stimulate the formation of neurites by secreting neurotrophic factors and axon guidance
molecules. The neuronal inﬂuence on the biology of a neoplasm was initially described several decades ago.
Since then, an increasing amount of experimental evidence strongly suggests the existence of reciprocal
interactions between cancer cells and nerves in humans. Moreover, researchers have been able to
demonstrate a crosstalk between cancer cells and nerve ﬁbers as a strategy for survival. Despite all these
evidence, a lot remains to be done in order to clarify the role of neurotransmitters, neuropeptides, and their
associated receptor-initiated signaling pathways in the development and progression of cancer, and response
to therapy. A global-wide characterization of the neurotransmitters or neuropeptides present in the tumor
microenvironment would provide insights into the real biological inﬂuences of the neuronal tissue on tumor
progression. This review is intended to discuss our current understanding of neurosignaling in cancer and its
potential implications on cancer prevention and therapy. The review will focus on the soluble factors released
by cancer cells and nerve endings, their biological effects and their potential relevance in the treatment of
cancer.(CEK), Institut d'Investigacions Biomèdiques Agustí Pi I S
arcelona, Spain. Tel.: +34 932275400x4013; fax: +34 9
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Tumor development, similar to what has been suggested for
normal organ homeostasis, should be regarded as a result of constant
mutual interactions between tumor cells and their surrounding
microenvironment. The communication between the tumor cells
and the microenvironment drives the process of tumor progression
[1]. Normally, cancer starts as a conﬁned disease, which if diagnosed
early, can be treated effectively by surgical removal of the primary
tumor. The invasion of cancer cells into surrounding tissues, resulting
in the development of distant metastasis, is the dangerous following
step. In fact, most of the cancer-related deaths are due to invasive
tumor growth and the subsequent increase of life-threatening
metastatic disease. Several cellular and soluble components of the
tumor microenvironment inﬂuence tumor progression, including the
cellular events related to the metastatic spread of the disease by
modulation of the biological behavior of the cancer cells. Moreover,
the tumor microenvironment is dynamically remodeled in parallel to
the progression of the disease. The recruitment of different cellular
component to the surrounding stroma will contribute to the creation
of a milieu of soluble factors and will also enhance the formation of
new blood and lymphatic vessels.
In the early seventies, Folkman et al. [2] showed for the ﬁrst time
the evidence for the ability of tumors to foster new blood vessels, a
process called neoangiogenesis. From then on, substantial efforts have
been invested to uncover the mechanisms of this process and to ﬁnd
new drugs able to limit the growth of a tumor by blocking its blood
supply [3,4]. The neovascularization of a tumor strongly inﬂuences
cancer progression, and actively contributes to the progression from a
dormant in situ lesion to a lethally metastatic disease. Vascular
endothelial growth factor A (VEGFA) and its receptor, VEGF receptor 2
(VEGFR2; also known as FLK1), have been demonstrated to play a
pivotal role during this process. For this reason, several anti-
angiogenic strategies aimed at inhibiting VEGFA and VEGFR2
signaling have been developed [5], although in some cases with
disputed results [6]. At present, VEGF-based therapies can increase
the survival in cancer patients only by months rather than years [7].
Another endothelial network, essential for tissue homeostasis in
the healthy individuals and a source of pathogenesis in different
diseases including cancer, is the lymphatic vasculature [8–10]. The
creation of new lymphatic vessels within the tumors, or lymphangio-
genesis, contributes to the early spread of cancer cells. For example, it
has been demonstrated that lymphoangiogenic factors inﬂuence the
metastatic disease [11]. Discrimination between blood and lymphatic
vessels has been a bit problematic in the past because of the shortage
of lymphatic endothelium speciﬁc markers. During the last few years,
the introduction of lymphatic markers such as LYVE-1 and podopla-
nin, has been a critical step in the right direction [11] helping to
improve the clinico-pathological analyses of lymphangiogenesis in
human cancer. In addition to showing that lymphangiogenesis is a
process related to human cancer onset, these studies have also shown
that expression of VEGF-C or VEGF-D is associated with lymph node
metastasis in several human tumor types, further highlighting the
importance of these growth factors for tumor spread [10,12].
Similar to the processes of neoformation of blood and lymphatic
vessels, several evidence point out to the possibility of the formation
of new nerve endings inside the tumors. The capacity of the tumors to
stimulate their own innervation in a way similar to neoangiogenesis
and lymphangiogenesis has been termed neoneurogenesis. Althoughthe presence of nerve endings within the tumors has been described
for bladder [13], eye [14,15], prostate [16], breast [17,18], pancreatic
[19] and colon cancer [20], and others [15,21], the neoformation of
axonwithin human tumors has only been described in prostate cancer
[22]. Independent of the formation of new nerve endings or axons
from the preexisting ones, there is an increasing body of research
suggesting that the neuropeptides and neurotransmitters present in
the tumor microenvironment play an important role inﬂuencing the
course of the disease.
The role of the nerve ﬁbers in the tumors was initially thought to
be mechanical, behaving as “paths” that allows the migration of the
perineural invading cells. However, now it has been suggested that
the nervous system is in fact functionally relevant, modulating a
complex network of mediators related to tumor progression. For
example, the suppression of the immune response in cancer has been
linked to the presence of neurotransmitters [23], and tumor
vascularization and changes in vessel density have been shown to
be affected by several neurotransmitters [24,25]. Moreover, cells
respond to neurotransmitters increasing their migratory activity
[26,27] and the presence of nerve ﬁbers within the tumors correlates
with a poorer clinical outcome [28] (Fig. 1). In addition, the
interaction between the nervous system and the tumors seems to
be reciprocal, since cancer cells are also able to secrete neurogenic
factors [29–31] and axon guidance molecules [32], therefore stimu-
lating and driving the ingrowth of new nerve endings to the tumor.
2. Presence and neoformation of nerve structures within
the tumors
The cross talk between cancer cells and nerve ﬁbers implies that
both counterparts secrete factors that favor the rapid growth of both,
making the neural-epithelial interaction amutually beneﬁcial process.
Thus, it is likely that the perineural space is enriched in soluble factors
that attract cancer cells favoring the process of perineural invasion. On
the other hand, cancer cells secrete neurogenic and axon guidance
molecules that would promote neurogenesis and the growth of nerve
endings that will inﬁltrate the tumor.
2.1. Perineural invasion
Although there is no consensus about the process of perineural
invasion (PNI), Batsakis offered the ﬁrst deﬁnition of PNI as tumor cell
invasion in, around, and through the nerves [33]. Since the idea of the
presence of cancer cells around the nerves was controversial, this
deﬁnition was later modiﬁed to propose that at least 33% of the
circumference of a nerve should be surrounded by tumor cells to be
referred to as PNI; anything less than 33% of tumor cells surrounding a
nerve is therefore not considered invasion (reviewed in [34]). Initially,
the observation PNI was thought to be cancer cells traveling through
the lymphatic vessels located within the nerve. However, it was
subsequently demonstrated that the perineural space is devoid of
lymphatic vessels and thus, PNI is a true physical phenomenon [35]
(Fig. 2).
The incidence and clinical signiﬁcance of PNI has also been
controversial, although in the majority of cancers it is associated with
a poorer clinical outcome [34] and in some of them its measure can be
used as an independent prognostic factor [36]. There are different
biological consequences of PNI that affect tumor progression. Besides
the use of nerve ﬁbers as physical support for migration, the perineural
Fig. 1. Representation of the therapeutic approaches targeting the nervous system and the mechanisms inﬂuenced during cancer progression. The signals released by the nervous
system can affect multiple pathways that will ﬁnally drive tumor progression and a poorer clinical outcome for the cancer patient. Several different therapeutic approaches to
improve patient prognosis are under investigation.
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protective niche for the cancer cells. This is nicely illustrated by the fact
that prostate and pancreatic cancer cells are more proliferative and
have decreased apoptosis when located in close proximity to a nerve
space [37,38]. In such environment, cancer cells can exploit the
advantage of the factors released by the nerve ﬁbers that create a
positive microenvironment for survival and proliferation. Besides,
proinvasive signals are released within the peripheral nerve milieu
inﬂuencing cancer cell migration (Fig. 2). Moreover, the formation of
new axons could be a consequence of PNI, since cancer cells synthesize
and secrete neurotrophic factors like NGF [29] and axon guidance
molecules like netrin-1 [39].
2.2. Neoneurogenesis
2.2.1. Experimental evidences of axonogenesis in cancer
Besides invading peripheral nerves and using them for migration, it
has been proposed that cancer cells stimulate their own innervations.
Thus, the concept of neoneurogenesis includes the development of
nerve endings (axons) towards the tumor. Cancer cells are able to
secrete neurite outgrowth-promoting molecules and axon guidance
molecules (see Sections 2.2.3 and 2.2.4) that would stimulate and drive
the growth of these new axons to particular areas of the tumor.
Several in vitro approaches suggest the existence of such mecha-
nism. The formation of the nervous system depends on the precise
mechanism of chemotactic axon guidance induced by molecular
gradients [40,41] and supported by extracellular matrix components
[42,43]. Extracellular matrix components like the ones included in
Matrigel support the axonal growth from explants of peripheral nerve-
dorsal root ganglia (DRGs) obtained from the lumbar spinal cord of
mouse embryos at 17 weeks of gestation [44]. A co-culture systemwith
DRGs and cancer cells has been successfully used to estimate neurite
outgrowth, its directionality towards cancer cells, and the existence of
cancer cell-nerve interaction, migration of cancer cells towards andthrough the nerves (PNI) and the growth rate of cancer cells. Using this
system, Ayala and collaborators have shown the directional outgrowth
of neurites from the DRGs toward human cancer cells in vitro in
prostate [22] and pancreatic cancer [38], providing support for the idea
of the process of neoneurogenesis in human cancers.
2.2.2. Potential mechanism of axonogenesis in tumors
Although the stimulation of neoneurogenesis by tumor-released
soluble factors has not been demonstrated in human tumors, it is
likely that the system used by cancer cells to induce neurite
outgrowth could be similar to the process of nerve recovery after
injury. In contrast with the central nervous system (CNS), the
peripheral nervous system (PNS) can support long-axon regeneration
after injury. In the adult PNS, the Schwan cells produce several growth
factors that can support axonal regeneration, including NGF, BDGF,
IGF, CNTF and others [45]. Moreover, for a successful axon growth and
elongation towards a target ﬁeld, neurons depend on the activation of
different signaling pathways shared by cancer cells. For instance, the
protein Akt is important for neuronal polarity; GSK3 activity is related
to microtubule stability and remodeling; and the PI3K family of
proteins regulates cell polarity, motility and chemotaxis during axon
speciﬁcation [46]. Several of the growth factors secreted by the
Schwan cells during axon regeneration are also secreted by cancer
cells, along with other soluble factors that are able to activate the
aforementioned signaling pathways in cells expressing their re-
ceptors. Thus, it is possible that within the tumor microenvironment,
axonogenesis could be under the control of the cancer-derived
signaling pathways similar to injury-induced axonal regeneration.
We also have to consider another particularity of cancer cells, like the
generation of their own extracellular matrix that would also support
axonal growth [44]. In agreement with this concept, neurite
outgrowth on muscle cell surfaces is also dependent on ECM
molecules [47]. Despite the axonal ingrowth into the tumor, we
cannot rule out the possibility of neogenesis of neuronal cells. Some
Fig. 2. Representation of the proposed reciprocal interaction between the nervous system and the tumor. 1. The nerves can secrete a milieu of factors that will promote cancer cell
survival, proliferation and 2. migration toward the nerve. Once in the proximity of the nerve area, tumor cells will found a low-resistant barrier, being able to either migrate through
the nerve or inﬁltrate it through 3. the endoneurium and 4. the epineurium. These different mechanisms will allow tumor cells to 5. migrate to distant sites. On the other hand, tumor
cell will secrete both 6. axon guidance molecules and 7. neurotrophic factors that would inﬂuence neurite outgrowth towards the tumor. This image has been created thanks to Servier
Medical Art. Adapted from [34]. PNI, perineural invasion; BMDC, bone marrow-derived cell.
108 M. Mancino et al. / Biochimica et Biophysica Acta 1816 (2011) 105–118authors have provided evidence that mesenchymal stem cells (MSC),
a bone-marrow derived population usually recruited by tumor cells,
were able to differentiate into functional neurons upon the activation
of the correct differentiation pathways (reviewed in [48]). Recently,
the transdifferentiation of cancer cells into functional endothelial cells
has been reported [49], demonstrating how far tumors can go to
create the most advantageous microenvironment for their
progression.
2.2.3. Cancer-related neurotrophic factors
One of the several evidence supporting the idea that cancer cells
can support the neoneurogenesis process is the fact that tumors can
secrete several neuronal growth factors and axon guidancemolecules.
It is interesting to note that most of the factors known to induce
neurogenesis, like NGF, BDNF, FGF or IGF-II [40] are usually secreted
by tumors with bad prognosis and these factors exert autocrine or
paracrine effects in the cancer cells. The creation of such a
microenvironment by cancer and nerve-secreted factors will favor
the progression of the disease by potentiating both the growth of the
cancer cells and the neurites.
The family of neurotrophic factors can be subdivided into
Neurotrophins, Neuropoietins, Insulin-like Growth Factors, Trans-
forming Growth Factors and Fibroblast Growth Factors among others
(Table 1). Neurotrophins display neurite-outgrowth-inducing and
survival-promoting effects on neuronal cells. Some of the most
relevant neurotrophic factors in cancer are discussed below.
2.2.3.1. Nerve growth factor. Nerve growth factor (NGF) was the ﬁrst
isolated neurotrophin and is well known for its role in nervous system
development. A major biological function of NGF is the maintenance
and survival of post-mitotic neurons, which makes it a strongcandidate for the treatment of neurodegenerative diseases. In
addition to its role in the development and maintenance of neuronal
cells, NGF has signiﬁcant effects on non-neuronal cells and during the
process of tumorigenesis.
NGF has been related to cancer progression in several tumor
types [50]. It is secreted by breast cancer cells but not by normal
breast epithelial cells [29], and the treatment directed against NGF
decreases breast cancer cell proliferation with a concomitant
increase in apoptosis, and inhibition of tumor angiogenesis
indicating that targeting of NGF is a potential therapeutic approach
in breast cancer [51]. Prostate malignant epithelial cells also secrete
NGF, which acts as an important autocrine factor for growth and
metastasis. Interestingly, intravenous gammaglobulin (IVIg) con-
tains natural antibodies against NGF. These antibodies inhibit
growth and differentiation of the NGF-dependent prostate cancer
cells demonstrating natural immunity to prostate cancer occurring
in healthy individuals [52].
In a recent work using a mousemodel of bone cancer pain, Mantyh
et al. [53] observed that as the tumor progresses into the bone, there is
nerve remodeling and a profuse sprouting of the sensory and
sympathetic nerve ﬁbers that induces pain in the animal. This
mechanism was mediated by the presence of NGF in the tumor
microenvironment and was reverted by the addition of anti-NGF [53]
or by the treatment with the Trk inhibitor ARRY-470 [54].
2.2.3.2. Brain-derived nerve growth factor. Brain-derived neurotrophic
factor (BDNF) is widely expressed in the brain, predominantly in the
hippocampus, cortex, and synapses of the basal forebrain [55]. Existing
data indicate that BDNF supports the long-term survival, differentia-
tion, and synaptic activity of neurons [55,56]. In patients affected by
Alzheimer's disease the mRNA levels of BDNF in the hippocampus and
Table 1
Summary of the neurotrophic factors family members and their receptors.
Family Member Signaling receptor
Neurotrophins Nerve growth factor (NGF) TrkA
Brain-derived neurotrophic factor (BDNF) TrkB
Novel neurotrophin-1 gp130
Neurotrophin-3 (NT-3) TrkC > TrkA and TrkB
Neurotrophin-4/5 (NT-4/5) TrkB
Neuropoietins Ciliary neurotrophic factor (CNTF) CNTF receptor complex (CNTFRa, gp130, LIFRb subunits)
Leukemia inhibitory factor (LIF or CDF/LIF) LIF receptor complex (gp130, LIFRb subunits)
Insulin-like growth factor Insulin-like growth factor-I (IGF-I) IGF type I receptor (IGF1R) > insulin receptor (IR)
Insulin-like growth factor-II (IGF-II) IGF1R, less so IR
Transforming growth factor Transforming growth factor α TGFα receptor
Transforming growth factor β (TGFβ1, TGFβ2, TGFβ3) TGFβ type I, II and III receptors
GDNF ligands Glial cell line-derived neurotrophic factor (GDNF) GFRA2, GFRA1
Neurturin (NTN) GFRA2
Persephin (PSP) GFRα4
Artemin (ARTN) RET receptor, GFR-alpha 3 as co-receptor
Fibroblast growth factors Acidic ﬁbroblast growth factor (aFGF or FGF-1) FGF receptors 1–4 (FGFR-1–4)
Basic ﬁbroblast growth factor (bFGF or FGF-2) FGFR-1–3
Fibroblast growth factor-5 (FGF-5) FGFR-1, FGFR-2
Other growth factors Transforming growth factor alpha (TGF-α) EGFR
Platelet-derived growth factor (PDGF: AA, AB and BB isoforms) PDGF a- and b- receptors
Stem cell factor (mast cell growth factor) c-kit
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for BDNF in preserving the integrity and function of cholinergic neurons
and their target tissues. Moreover, BDNF and its high afﬁnity receptor
(tropomyosin receptor kinase B, TrkB) are expressed in several tumor
types. For instance, in hepatocellular carcinoma patients both mRNA
and protein levels of BDNF are highly expressed in the tumor compared
to the undetectable levels in normal liver tissue [58]. Moreover, the
serum levels of BDNF are correlated with the status of microsatellites
and tumor recurrence, suggesting BDNF as a potential prognostic
marker in hepatocellular carcinoma [58]. Using immunohistochemical
techniques, high expression of BDNF and TrkB has been also observed
in human prostate and bladder cancer, suggesting a predictive role in
their diagnosis and/or management [59,60]. Recently, the selective Trk
inhibitor AZ623 has been shown to inhibit BDNF-mediated neuroblas-
toma cell proliferation and signaling. Furthermore, treatment with
AZ623 combinedwith topotecan resulted in the prolonged inhibition of
tumor regrowth and a synergistic effect with topotecan [61].
2.2.3.3. Novel Neurotrophin-1. Novel neurotrophin-1 (NNT-1)/B cell-
stimulating factor-3 (BSF-3), also reported as cardiotrophin-like
cytokine (CLC), belongs to the interleukin 6 (IL-6)-family of cytokines
[62,63]. Similar to IL-6, it exerts regulatory effects on normal B cell
functions using the gp130 signaling subunit as a part of its receptor
complexes [64]. The roles of NNT-1 in growth, survival, drug
resistance, and migration have been examined within the bone
marrowmicroenvironment of multiple myeloma (MM) cells suggest-
ing potential utility of novel therapies targeting NNT-1 cascades [65].
2.2.3.4. Neurotrophin 3 (NT3) and neurotrophin 4/5 (NT4/5). The
neurotrophins (NT) family, along with NGF and BDNF, also includes
neurotrophin 3 (NT-3) and neurotrophin 4/5 (NT-4/5). In addition,
NT-3 and NT-4/5 share two classes of receptors with NGF and BDNF,
the p75 neurotrophin receptor (p75NTR) and the tyrosine kinase Trk
receptors family (TrkA, TrkB, TrkC). Mainly, the signaling pathways
activated by Trk tyrosine kinase receptors are involved in the
regulation of survival and differentiation of neuronal cells [66].
However, recent studies investigating neurotrophin-mediated signal-
ing in non-neuronal cells have demonstrated an involvement of the
neurotrophins and their tyrosine kinase receptors in tumor growth
and in progression of non-neuronal cancers. NT-3 is overexpressed in
human pancreatic cancers [67], melanoma cells [68], medullar thyroid
carcinoma [69], lung [31], pancreatic [70], prostatic [71] and ovariancarcinomas [72]. The overall view is that, as is the case with classic
tyrosine kinase receptors, deregulation of kinase activities through
various mechanisms generates survival signals via the PI3K/Akt and
Ras/MEK/MAPK pathways, which in turn promote tumor progression
[73]. These signaling events should be validated as therapeutic targets.
2.2.3.5. Transforming growth factors. Transforming growth factors
(TGFs) are broadly accepted as a prototype of multifunctional growth
factors andmaster switches essential for the regulation of several life-
processes, such as development, repair, cell cycle control, differenti-
ation, extracellular matrix formation, immune functions, angiogene-
sis, chemotaxis, and hematopoiesis [74–77]. The TGFs-superfamily
includes several prominent members, including activins, bone
morphogenetic proteins (BMPs), growth/differentiation factors
(GDFs), and the glial cell line-derived neurotrophic factor (GDNF)
subfamily associated with a common cysteine knot motif [78], also
shared by other cytokines including the neurotrophins and platelet-
derived growth factor (PDGF). Perturbations in TGFs signaling have
been implicated in various human diseases, including cancer [79].
Indeed, during tumorigenesis TGFs secreted from tumor cells often
lose their inhibitory function in favor of their oncogenic activity [80].
In humans, the overexpression of TGFs has been associated with
breast, colon, esophageal, gastric, hepatocellular, lung and pancreatic
cancer [81–83] correlating with tumor progression, metastasis,
angiogenesis and poor prognostic outcome [81–83].
TGFs are also expressed in the nervous system carrying out several
neural functions like key roles in the regulation of neuronal survival
[84,85] and the orchestration of repair processes in the nervous
system [86].
Current therapeutic approaches to modulate TGFs signaling
involve antagonism of TGF-β ligand binding to the heteromeric
receptor complex with isoform-selective antibodies, such as lerdeli-
mumab (TGF-β2) [87] and metelimumab (TGF-β1) [88] or the pan-
neutralizing antibody GC-1008 [89], and intracellular inhibition of the
type I TGF-β receptor kinase with small-molecule inhibitors, such as
LY550410, SB-505124 or SD-208 [90–92]. Alternatively, expression of
TGF-β isoforms can be inhibited by antisense technology targeting
mRNA for sequence-speciﬁc degradation [89]. In addition to the
canonical SMAD signaling pathway downstream of the TGF-β type I
receptor, TGF-β can also activate the JUN-N-terminal kinase (JNK) and
mitogen-activated protein kinase (MAPK14; p38) pathways [93].
These SMAD-independent pathways provide different points of
Table 2
Summary of some axon guidance molecules and their receptors known to be related
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signaling.with tumor progression.
Family Member Signaling receptor
Netrins Netrin-1 Deleted in colorectal cancer (DCC),
Uncoordinated-5 (UNC-5)
Netrin-3/NTNL2 Deleted in colorectal cancer (DCC),
Uncoordinated-5 (UNC-5)
Netrin-4/β Deleted in colorectal cancer (DCC),
Uncoordinated-5 (UNC-5)
Netrin-G Deleted in colorectal cancer (DCC),
Uncoordinated-5 (UNC-5)
Ephrins Ephrin A ligand EphA receptor
Ephrin B ligand EphB receptor
Semaphorins Semaphorins 1–7 Plexins, Neuropilins
Slit Slit 1–3 Roundabout 1–4 (ROBO 1–4)2.2.3.6. Fibroblast growth factors. FGFs consist of a large cytokine
family with several biological roles. Given the complexity of FGF
signaling similar to TGFs, it is difﬁcult to make generalizations about
their role in development and differentiation. Fibroblast growth
factors (FGFs) signaling through FGF receptors (FGFRs) affect
fundamental developmental pathways, from mesoderm patterning
in the early embryo [94] to the development of multiple organ
systems [95]. As a consequence, any abnormalities in FGFs function
lead to a variety of developmental defects [96] and/or growth of
several cancers by directly driving cancer cell proliferation [97,98] and
survival [99], and by supporting tumor angiogenesis [100,101]. FGFs
are major determinants of neuronal survival both during develop-
ment and during adulthood [102].
Several FGFRs tyrosine kinase inhibitors (TKIs) are currently in the
early phases of clinical trials. Since FGFRs and VEGFRs share kinase
domains with high structural similarity, several of FGFRs TKIs also
inhibit VEGFRs (for example, TKI258 [103], BIBF 1120 [104], Brivanib
[105] and E7080 [106]). This dual inhibition has the evident
advantage of targeting two of the most important proangiogenic
growth factors simultaneously. On the other hand, targeting multiple
kinases might also amplify the side effects of these compounds. For
these reasons, many laboratories are trying to develop therapeutic
antibodies that are able to minimize the side effects of targeting FGFRs
[107,108].2.2.4. Axon guidance molecules in cancer
2.2.4.1. Netrins and their receptors. Netrins belong to a conserved
family of secreted proteins having regional homology to laminins and
are able to regulate axonal outgrowth [109–111]. The cellular
expression of either receptors belonging to the DCC (deleted in
colon cancer) or UNC5 families of Netrin-1 receptors determines the
direction of Netrin-dependent neuronal outgrowth [112,113]
(Table 2). DCC and UNC5 proteins are single-pass transmembrane
receptors, with immunoglobulin domains. Moreover, UNC5 contains a
thrombospondin type-I domain while DCC contains ﬁbronectin type-
3 domains [114]. The DCC receptors, which include the structurally
similar Neogenin receptor, mediate neural attraction, while a complex
of DCC and UNC5 receptor families is able to mediate repulsion
[115,116]. Studies performed during the last years have found
functioning Netrin molecules outside the nervous system (for
example in the pancreas, intestine [117,118], lung [119], kidney,
heart and vasculature [120,121]), suggesting their potential role in the
development of these organs by affecting the migration of diverse
types of cells.
In addition, regulation of the expression of Netrin-1 and its receptors
may play a role in tumorigenesis. In fact, reduction in Netrin-1
expression has been detected in tumors of the prostate and the nervous
system [122,123]. In cancers of the brain, stomach, pancreas, colorectal
and testicle, low levels of somatic mutations of DCC have been detected
[39]. Exogenous soluble Netrin-1 is able to reducemigration and induce
increased levels of markers of early neuro-ectodermal differentiation in
embryonic carcinoma cells suggesting a potential role for Netrin-1 in the
regulation of differentiation in human embryonic carcinoma cells
[124,125]. Netrin-1 and Neogenin have also been found in the
mammary gland terminal end-buds that are implicated in maintaining
adhesion between cap cells and luminal cells [126]. Overexpression of
Netrin-1 has been observed in a large fraction of human metastatic
breast tumors conferring a selective advantage for tumor cell survival
and thus it could be a potential target for alternative anticancer
therapeutic strategies [127].2.2.4.2. Eph/Ephrin. The Eph receptors (Table 2) form the biggest
subgroup of the receptor tyrosine kinase (RTK) family. Eph receptors
and their ephrin ligands have been implicated in diverse develop-
mental and neurological functions, including hindbrain development
in vertebrates and tissue patterning [128,129]. In addition, a variety of
other biological activities are modeled through Eph/ephrin, including
cell–cell interaction, cell migration, and increase in tumor growth,
survival and metastatis. Increased Eph/ephrin signaling pathway
activation has been shown to be associated with angiogenesis in
several human cancers, including breast [130], lung [131], prostate
[132] cancers, melanoma [133], and leukemia [134]. All these ﬁndings
have been used to further advance novel cancer treatment methods.
EphA2 (an Eph receptor) can be targeted by an antibody in aggressive
lung tumors [135]. Another therapeutic approach could be the use of
mimetic peptides that are able to target the ligand-binding domain of
EphA2, and thus competing with ephrin ligands for binding [136,137].
2.2.4.3. Semaphorins. Originally described as axon guidance molecules
inﬂuencing the development of the central nervous system [138],
semaphorins and their receptors have also been found to be released
by several types of cancer cells [139–141] and by cells in the tumor
microenvironment [142] establishing their own autocrine regulatory
loops to enhance cell survival. Unfortunately, our knowledge of
semaphorins versatile signaling pathways is still lacking, and further
studies on the semaphorins-mediated crosstalk between tumor cells
and tumor stroma are needed. Developing ways to interfere with
semaphorin-mediated signals might be a promising anti-cancer
strategy.
3. Neurotransmitters and neuropeptides in cancer
Although several neurotrophic factors, axon guidance molecules,
neuropeptides and neurotransmitters have been identiﬁed as medi-
ators of the tumor-nerve interaction, the complex network of factors
released as consequence of this interaction is largely unknown. Awide
comprehensive characterization of both the soluble factors and their
receptors expressed by cancer cells, or even by the cellular
compartment of the tumor microenvironment, and related to tumor
progression and metastasis will generate a new area for target
discovery and therapeutic intervention.
To this date, several neurotransmitters and neuropeptides have
been related to tumor progression mainly by stimulating the
migration ability of cancer cells, a key event in the dissemination of
tumor cells to distant sites. In the following section, we will describe
some of the neurotransmitters and neuropeptides related to tumor
progression (summarized in Tables 3 and 4), and we will discuss the
possibility of their inhibition as a potential therapy. Although by
themselves, most of these factors might not be essential for tumor cell
survival, they have been shown to promote tumor growth and affect
Table 3
Summary of the most relevant neurotransmitters related to tumor progression.
Family Member Signaling receptor
Amino acids Aspartate NMDA receptor
Glutamate (Glutamic acid) Metabotropic glutamate receptor, NMDA receptor, Kainate receptor, AMPA receptor
Gamma-aminobutyric acid GABAB receptor, GABAA, GABAA-ρ receptor
Glycine Glycine receptor
Acetylcholine Acetylcholine Muscarinic acetylcholine receptor, Nicotinic acetylcholine receptor
Monoamine (Phe/Tyr) Dopamine Dopamine 1–5 (D1–5) receptors
Norepinephrine (noradrenaline) α-β Adrenergic receptors
Epinephrine (adrenaline) α-β Adrenergic receptors
Monoamine (Trp) Serotonin (5-hydroxytryptamine) 5-HT1-7 receptors
Melatonin MTNR1 A–B–C receptors
Monoamine (His) Histamine H 1–4 receptors
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neurotransmitters and neuropeptides can activate signaling pathways
related to cell proliferation and survival, including the PI3K,MAPK and
Akt pathways [143], their inhibition should sensitize the tumors to the
current chemo- or targeted therapies. Moreover, in some particular
cases cancer cells can be inﬂuenced on their hormone dependency,
since some cancer cells lost their dependence on growth factors when
they are located in the proximity of a perineural space [144].
3.1. Classiﬁcation of neurotransmitters and neuropeptides
Searching for the nervous system (speciﬁcally the autonomous
nervous system) in the Pubmed or any scienceweb in general, it is very
common to ﬁnd its classical description as divided into two opposed
branches able to regulate autonomic functions of organs and tissues
that are not under the central control: the sympathetic and the
parasympathetic nervous system. The products of these systems are
mainly 1)molecular messengers able to regulate multiple functions in
the central and periphery nervous system, 2) potent cellular growth
factor for normal cells, and 3) deep-seated signaling peptides in
autocrine/paracrine stimulation, proliferation and migration of tumor
cells.
The total number of neurotransmitters is not known, but is likely
over 100 [145]. Despite this diversity, these agents can be classiﬁed
into two large categories: neuropeptides and small-molecule neuro-
transmitters. Neuropeptides are transmitter molecules composed of 3
to 36 amino acids. Individual amino acids, such as glutamate andTable 4
Summary of the most relevant neuropeptides related to tumor progression.
Family Member
Neurohypophyseals Vasopressin
Oxytocin
Neurophysin I
Neurophysin II
Neuropeptide Y Neuropeptide Y
Pancreatic polypeptide
Peptide YY
Corticotropin-releasing factor Corticotropin (adrenocorticotropic hormone
Opioids Dynorphin
Endorphin
Enkephaline
Secretin
Motilin
Secretins Glucagon
Vasoactive intestinal peptide
Growth hormone-releasing factor
Somatostatins Somatostatin
Tachykinins Substance P
Neurokinin A
Neurokinin B
Other neuropeptides Bombesin
Gastrin releasing peptideGABA, as well as acetylcholine, serotonin and histamine, are much
smaller than neuropeptides and are therefore called neurotransmit-
ters. In general, as a consequence of differences in the rate of
transmitter release, neurotransmitters mediate rapid reaction, where-
as neuropeptides tend to modulate slower functions [27].
The standard set of criteria used to corroborate that the supposed
molecule is indeed a NT/neuropeptides at a given synapse are: 1) The
substancemust be present within the pre-synaptic neuron, 2) Speciﬁc
receptors for the substance must be present on the post-synaptic cell
and, 3) The substance must be secreted as a consequence of pre-
synaptic depolarization, which must occur in a Ca2+-dependent
manner.
3.2. Most common neurotransmitters in cancer
The cancer incidence and progression seem to be strongly
dependent on psychosocial factors [146]. Stress-related situations
can induce the release of neurotransmitters and/or hormones that will
further inﬂuence tumor onset, development and progression [24,147].
3.2.1. Epinephrine and norepinephrine
Catecholamines, also known as stress-neurohormones (or stress-
mediators) due to their increased concentration in response to stressful
events [148], are the most studied neurotransmitters for their role in
carcinogenesis and tumor progression. Catecholamines are derived
from the amino acid tyrosine. Epinephrine and norepinephrine,
secreted mainly from the adrenal medulla and the sympathetic nerves,Signaling receptor
Vasopressin receptor
Oxytocin receptor
?
?
Neuropeptide Y receptors NPY1R, NPY2R, PPYR1, NPY5R
PPYR1
NPY2R
) Corticotropin receptor
κ-opioid receptors
μ1 opioid receptor Nμ2 and δ opioid receptors Nκ1 opioid receptors
Enkephaline receptors
Secretin receptor
Motilin receptor
Glucagon receptor
Vasoactive intestinal peptide receptor
Growth hormone-releasing factor receptor
Somatostatin receptor
NK1NNK2NNK3
NK2NNK3NNK1
NK3NNK2NNK1
BB 1–4
BB 2
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Recently, epinephrine and norepinephrine releases have been linked
with stress-induced tumor-growth and progression. In fact, that these
neurotransmitters can directlymodulate several mechanisms related to
tumor progression, such as cell proliferation, survival, andmigration. In
ovarian cancer cells, epinephrine and norepinephrine canmodulate cell
proliferation, survival and tumor angiogenesis through the activation of
the β-adrenergic receptor (βAR)– cyclic AMP (cAMP)– protein kinase A
(PKA) pathway [24,149]. βAR activation has been shown to increase
metastasis formation in breast, lung and colon cancer models [150–
152], and to accelerate growth in mammary tumors [153,154]. The use
of β-blockers has been proven efﬁcient in almost all the studies to
overcome the pro-metastatic effects of βAR activation.
There are several mechanisms underlying the promotion of
metastasis by epinephrine and norepinephrine. In a recent study,
the activation of the β-adrenergic signaling in an orthotopic breast
cancer mouse model of stress-induced neuroendocrine activation
induced a 30-fold increase in the metastasis formation. This was
accompanied by an increased recruitment of macrophages into the
primary tumor site [155]. In other systems, these neurotransmitters
have been reported to facilitate the angiogenic switch and to induce
the secretion of VEGF and IL-6 by cancer cells [24,156,157].
From the prevention and therapeutic point of view, it is interesting
to consider the potential role of cathecolamines in stress-induced
cancer development. In addition to their role in tumor progression,
their physiological concentrations related to stress situations or
depression can favor the initiation of cancer [149,158]. Moreover,
propranolol, a β-blocker, was shown to have preventive effects in the
development of pancreatic ductal adenocarcinoma in mice [159],
supporting the role of the catecholaminergic system in cancer
development.
3.2.2. Dopamine
The effects of the catecholamine neurotransmitter dopamine on
tumor growth are opposite to that of norepinephrine and epineph-
rine. Dopamine exerts antagonic effects on cell growth in normal and
cancer cells; it promotes proliferation of non-transformed cells but
has antiproliferative effects in cancer cells. In gastric cancer cells,
dopamine inhibits IGF-1-induced proliferation by up-regulating the
cell cycle regulator KLF4 [160]. The administration of dopamine has
also been linked to growth diminution in several tumors models, such
as stomach, breast and colon cancer [161,162]. Dopamine has been
shown to inhibit VEGF–induced angiogenesis and to decrease the
mobilization of endothelial progenitors from the bone marrow
[162,163]. Most importantly, dopamine has shown signiﬁcant
synergism with conventional anticancer drugs, like doxorubicin or
5-ﬂuorouracil (5-FU) [162].
Despite the anti-tumor effects of dopamine, there is controversy
about the lack of its expression and cancer development [164,165].
Dopamine is a well-known inhibitor of prolactin, a growth factor for
cancer cells. Thus, dopamine inhibition could promote tumor growth
by increase in prolactin levels, as has been suggested for breast cancer
[166,167]. However, there is no clear consensus about the role of the
dopaminergic system in cancer development, and more epidemio-
logical data is needed in order to get a broader picture of dopamine
and cancer risk.
3.2.3. Serotonin
Serotonin is a neurotransmitter and serves critical cognitive and
behavioral functions in humans, with numerous important peripheral
functions in the gut, vasculature, immune system, and at wound sites
[168–170]. Serotonin is well known for its role as a neurotransmitter
involved with mood regulation; but it also has a role in normal
mammary gland development, where it helps to regulate lactation
and involution inﬂuencing the mechanisms of homeostasis in the
mammary epithelium [171,172]. Deregulation of these epithelialhomeostatic systems is in part responsible for breast cancer onset:
breast cancer cell lines show signiﬁcantly elevated tryptophan
hydroxylase 1 (TPH1; a serotonin receptor) transcript and protein
levels. Since TPH1 is rate limiting factor for serotonin synthesis in
mammary epithelial cells, as well as other systems [173], breast
cancer cells synthesize excess serotonin, which they then employ to
sustain their growth advantages [174].
Regulation of epithelial homeostasis by serotonin is not restricted
to the mammary epithelium. In fact, serotonin has also been
implicated in epithelial homeostasis of the lung, pancreas, liver and
prostate [175–178]. Therefore, variation in local serotonin signaling
may be a common mark of cancer progression in epithelial tumors.
New therapeutic approaches modulating serotonin signaling are
under investigation; for example, Keyhole limpet Hemocyanin (KLH),
a copper-containing respiratory pigment found in the mollusk,
Megathuracrenulata, that targets the serotonergic signaling pathway
has been shown to inhibit cellular proliferation in human cancer cell
lines of the breast, esophagus, pancreas, and prostate [179]. Moreover,
three drugs in wide use to treat thought disorders — paliperidone,
pimozide and risperidone that are potent and well-tolerated in-
hibitors at serotonin receptor 7, are under investigation for growth
factor deprivation in an adjunctive role in glioblastoma treatment
[180].
3.2.4. Acetylcholine
Acetylcholine is the neurotransmitter of the parasympathetic
system and its biological activity is mediated by nicotinic and
muscarinic acetylcholine receptors (n-AchR and m-AchR, respec-
tively) in the central and peripheral nervous system [181]. The n-
AchR is a Ca2+ or Na+ ion channel whereas the m-AchR belongs to
the family of G-protein coupled receptors with seven transmem-
brane spanning domains.
Acetylcholine is one of the most important neurotransmitters
implicated for pharmacotherapy. Its rapid inactivation is facilitated by
the cholinesterase enzymatic cleavage, which is critical in synapses
with very high repetition rates such as the neuro-muscular junction in
skeletal muscle. However, it is also implicated in slower synaptic
activity in the peripheral autonomic nervous system, as well as in the
central nervous system. In 1989, for the ﬁrst time Schuller and co-
workers [182] suggested the potential role of the autonomic nervous
system in the regulation of cancer cells. They showed that nicotine as
well as 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK; a
tobacco-speciﬁc nitrosamine) stimulated the proliferation of human
small cell lung cancer (SCLC) cells via binding to n-AChRs, and the
selective agonist for βARs, isoproterenol, stimulated the growth of the
human lung adenocarcinoma cells [182].
In recent years, n-AChRs have been identiﬁed as important
regulators of several other cancer types. In fact, activation of this
pathway has been shown to induce the growth of mesothelioma cells
(also displaying anti-apoptotic effects) [183]; to induce the proliferation
of colon cancer cells [184]; and to stimulate the proliferation,
angiogenesis, and cell migration of gastric cancer cells as a consequence
of nicotine-induced prostaglandin E2 activity, cyclooxigenase-2 (COX-
2), and VEGF augmentation [185].
The m-AChRs, the other acetylcholine family receptors, are also
expressed in most SCLC and many non-small cell lung carcinomas
(NSCLC) [186]. A growth-promoting effect of m-AChRs, mediated by
transactivation of EGFR and subsequent activation of ERK, has been
demonstrated in colon cancer cells [187]. Activation of theMAP kinase
by m-AChRs induces cell proliferation and protein synthesis in human
breast cancer cells [188].
For these reasons, the potential therapeutic effects of both the
nicotinic andmuscarinic receptor antagonists are under investigation.
For example, NSCLC cells express n-AChRs and the activation of these
receptors by agonists, namely nicotine, inhibits apoptosis, whereas
receptor antagonists have a pro-apoptotic effect [189]. Some
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nary disease (e.g. darifenacin) have also been shown to have the
ability to arrest tumor progression in nude mice [190]. The treatment
of SCLC cells with M3R antagonists inhibited cell growth both in vitro
and in vivo, and decreased MAPK phosphorylation in tumors in nude
mice suggesting that M3R antagonists may be useful adjuvant for
treatment of SCLC [191].
3.2.5. Glutamate
Glutamate is the major excitatory neurotransmitter in the
mammalian central nervous system (CNS) [192]. It works through
two classes of receptors: ionotropic glutamate receptors and
metabotropic glutamate receptors. Based on their structural similar-
ities, the ionotropic glutamate receptors are subdivided into three
groups: AMPA, NMDA and Kainatereceptors. On the other hand,
metabotropic glutamate (mGlu) receptors are G-protein coupled
receptors (GPCRs) generally divided into subgroups (so far, eight
members of mGluRs have been identiﬁed) based on sequence
similarity, pharmacological and intracellular signaling mechanisms.
In addition to the well-established role of the glutamaergic system in
the CNS, emerging evidences point to a role for glutamate and its
receptors in peripheral tissues [193,194] and in cancer [195,196]. In
fact, the expressions of glutamate and glutamate receptor subunits
have been found in several cancer cell lines and tumors, i.e., colorectal
cancer [197,198], glioma [199–201] gastric cancer [202], prostate
cancer [203], oral squamous cell carcinoma [204], melanoma
[205,206] and osteosarcoma [196].
In the clinical setting, the expression of glutamate receptor could
be used for prognostic purposes; it has been demonstrated that oral
squamous cell carcinoma overexpresses the glutamate receptor,
NMDAR1, and the up-regulation of NMDAR1 is well-correlated with
the TN stage tumor size, presence of lymph node metastases and
poorer survival [207]. In colorectal carcinoma, overexpression of
mGluR4 is associated with poor prognosis [198]. And in colon cancer
cell lines, elevated mGluR4 expression or activation by agonists
promotes cell survival in the presence of 5-Fluorouracil (5-FU),
whereas decreased mGluR4 expression or inactivation by antagonists
leads to cell death, suggesting that the cancer cells overexpressing
mGluR4 are protected against 5-FU cytotoxicity and becoming 5-FU
resistant [197]. On the other hand, the expression of mGluR4 has been
shown to be inversely correlated with tumor aggressiveness,
spreading and recurrence in medulloblastoma [208], indicating a
new role of glutamate and its receptor in tumor progression, thus
showing that the clinical signiﬁcance of glutamate receptor expres-
sion may be different among different tumors.
3.2.6. Gamma-aminobutyric acid
Gamma-aminobutyric acid (GABA) is the major inhibitory neuro-
transmitter of the central nervous system, where it has been shown to
play a role in pathological conditions [209]. Mostly, GABA works with
two classes of cellular receptors: (a) the ionotropic GABAA and GABAC
receptors, which are oligomeric chloride channels [210,211] and (b)
the metabotropic GABAB receptor. The GABAB receptor is a member of
the serpentine or seven-helix receptor family and is related to the
chemokine receptors and catecholaminergic receptors, both of which
have been shown to be involved in the regulation of leukocyte and
tumor cell migration [212].
Several reports have suggested a relationship between the
GABAergic system and oncogenesis [213,214]. In pancreatic
duct epithelial cells, all components of the stimulatory network
(adenylyl cyclase-dependent intracellular signaling downstream of
beta-adrenoreceptors (β-ARs)) are upregulated resulting in the release
of epidermal growth factor, vascular endothelial growth factor and
arachidonic acid. At the same time, GABA, which inhibits this pathway
by blocking the activation of adenylyl cyclase, is suppressed [215].
Conversely, GABA content is increased in several types of humantumors such as colon, gastric, ovarian, and breast cancers [216–219].
GABAA receptor is upregulated in sporadic breast cancer [220] and
pancreatic adenocarcinomas [221]. These ﬁndings suggest that in-
creased GABA levels could reﬂect a local anti-tumor response. For these
reasons the effect of GABA and its analogs, such as baclofen, on the
growth of cancer are under investigation as potential new therapeutic
target [222].
3.3. Neuropeptides in cancer: tachykinins
Neuropeptides are small polypeptides synthesized by several cell
types in the soma on the rough endoplasmic reticulum (RER) as larger
pro-peptide molecules that are post-translationally cleaved before
they arrive at the Golgi apparatus. In the trans-Golgi network, the
cleaved neuropeptides are packaged into secretory vesicles and
transferred, via the so-called “fast axonal transport” to the pre-
synaptic terminal. These signaling peptides play a crucial role in the
regulation of exocrine and endocrine secretion, smooth muscle
contraction, pain transmission, ﬂuid homeostasis, blood pressure
and inﬂammation. In addition to these traditional functions, neuro-
peptides can also act directly as potent cellular growth factors for
multiple cell types [223] and could play an important role in cancer
progression [26,27].
Neuropeptides function peripherally as paracrine and endocrine
factors to regulate diverse physiologic processes and act as neuro-
transmitters or neuromodulators in the nervous system. In the large
majority of cases, the receptors which mediate signaling by
neuropeptides are members of the superfamily of G-protein-coupled
receptors (GPCRs) [224]. In cancer, they can also act as autocrine and
paracrine factors [225] regulating several processes related to tumor
progression.
Several neuropeptides have been implicated in tumor progression,
including bradikinin, colecistokinin, neuropeptide Y, and substance P.
Substance P (SP) belongs to the tachykinin family, and is synthesized
by macrophages, neuronal, endothelial, and epithelial cells [226].
Human tachykinins, including substance P (SP), neurokinin A and
neurokinin B are codiﬁed by the TAC1, TAC3 and TAC4 genes, and
interact with a family of G-protein coupled receptors (GPCRs), the
tachykinin receptors NK1, NK2 and NK3, respectively [226]. SP is an
undecapeptide involved in mediating several physiological processes
including the process of wound healing where it facilitates the
neurogenic inﬂammation and regulation of hematopoiesis [227,228].
Both SP and NK1 are overexpressed in several cancers including
breast, ovarian, prostate, pancreas, thyroid and glioblastoma, among
others [226].
In breast cancer, SP and its receptors are implicated in the
acquisition of oncogenic properties and in the facilitation of bone
marrow metastasis [229–232]. The activation of NK1 receptor by SP
induces signaling pathways like PI3K, the NF-κB pathway, and
mitogen-activated kinases (MAPKs), promoting the proliferation
and survival of cancer cells. Given the relevance of SP-NK1 signaling
in cancer, several efforts have been invested in developing therapeutic
inhibitors against NK1 [233] or SP [234].
4. Neurosignaling in inﬂammation and cancer progression
After tissue injury, sensory nerves release neuropeptides that
mediate neurogenic inﬂammation. Neuropeptides can orchestrate the
wound healing process by modulating a network of mediators like the
immune system cells. Moreover, neuropeptides like SP or CGRP act as
potent mediators of neurogenic inﬂammation by increasing the
vasculature permeability and favoring edema formation [235].
The release of neuropeptides in an injured tissue could serve as the
initial signal to promote the recruitment of immune cells [236]. These
cells, will in turn release cytokines that will induce the synthesis of
neurotrophic factors necessary to stimulate neurite growth. This idea
114 M. Mancino et al. / Biochimica et Biophysica Acta 1816 (2011) 105–118is supported by the fact that nerve ﬁbers cannot exist without a local
control by growth factors. For instance, immune cells can synthesize
neuropoeitic cytokines like IL-6 that can induce neuronal survival,
differentiation and neurite outgrowth [143]. Experimental evidence
also supports the role of SP in skin wound healing by inducing neurite
outgrowth [237]. In fact, wound healing can be accelerated by the
administration of sensory neuropeptides [238].
Despite inducing the recruitment of different immune system cells
in an injured site, neuropeptides can also induce immunosuppression
by heterologous desensitization of chemokine receptors. During
heterologous sensitization, the activation of a given GPCR can induce
the phosphorylation of the cytoplasmic tails of another GPCR, which
then becomes insensitive to further signaling. Chemokine receptors
present in immune cells have been shown to be heterologous
inhibited by neuropeptides like opioids and VIP, contributing to
immunosuppression [239].
Although inﬂammation after injury is related to tissue regenera-
tion, several evidences support the idea that when the inﬂammation
becomes chronic or is maintained for a long period of time, several
pathological processes are activated. In fact, it is believed that chronic
inﬂammation provides a favorable microenvironment to support cell
transformation through the release of cytokines and growth factors
that support epithelial growth. In this scenario, it is plausible that the
factors released as a consequence of neurogenic inﬂammation could
also provide a milieu of factors that would favor cell transformation
[240].5. Concluding remarks: the nervous system as a therapeutic target
for cancer
Even though the true implication of the nervous system in cancer
progression has begun to be elucidated only in the past few years, it is
clear that a better understanding of how this reciprocal system
operates will provide new insights for therapeutic intervention
against cancer progression.
It is important to remark that the factors released by the nervous
system as a consequence of the psychological and social pressures
might lead to (or even enhance) cancer progression by changing the
efﬁciency of the drugs used for the treatment of cancer. Since the
factors released by nervous system in response to stress seem to have
important inﬂuence on efﬁcacy of drugs, it might be essential to revisit
the method of testing the drugs in vivo that are currently performed
using stabulated stress-free animals. Cancer handling using conven-
tional treatments such as chemotherapy, or even surgical ablation,
usually escape the difﬁculties added by nervous system and life-style
factors coming from and regulated by tumor host environment. As a
consequence, the initiation, progression and especially relapse of the
most common human cancers, as we documented above, are strongly
inﬂuenced by an imbalance between stimulatory and inhibitory
nervous system factors. Following this line of thought, it seems quite
naïve to challenge tumors only by blocking relevant cellular signaling
molecules, such as tyrosine kinase, usually overexpressed in some
cancer cells. A different approach, resembling the one involved with
hormone-responsiveness, and that considers the identiﬁcation of
hyper and hypoactive neurotransmission in each patient seems to be
necessary.
Several experimental evidences provide support for the use of
neurotransmitter inhibitors or neuropeptide receptor antagonists for
the treatment of cancer. For example, as discussed earlier, cancer-
related bone pain is caused by the sprouting of sensory nerves within
the bone, a process that can be reverted by the inhibition of NGF. Since
inhibition of NGF has also been shown to have anti-tumorigenic effect,
such therapies that prevent the reorganization of sensory nerve ﬁbers
in cancer could provide, not only a potential treatment against cancer
but also a cure for neuropathic pain that accompanies it [240,241].Acknowledgments
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